The 96.0% gross margin versus 9.7% operating margin gap in 2026Q2 implies SG&A and operating costs consume roughly 86% of gross profit, which reflects a business model whose true earning power cannot be judged at the gross line. Investors should treat the 11.0% net margin as the more representative margin, though it was distorted in prior quarters (for example, -34.7% in 2025Q4), meaning the recent swing to profitability appears early-stage rather than stabilized, and warrants further investigation of cost durability.

An ROIC above 100% paired with ROE of only 4.9% suggests the company's accounting equity base, rebuilt after the 2025Q4 deleveraging, understates the true economic capital tied up in the lead product, and any ROIC reading this extreme should be discounted as a denominator artifact rather than evidence of compounding returns. Compared to Lineage Cell Therapies' -84.4% ROIC, FENC's return profile is materially stronger, but the trend cannot yet be confirmed as durable given ROIC data availability is sparse across the ten-quarter window.

A DPO consistently above 270 days since 2025Q4 suggests payables are not operating as a financing mechanism but may instead capture milestone-related liabilities, so the negative CCC should not be read as working-capital efficiency or supplier creditworthiness. The sharp DIO swing from 326 days in 2025Q3 to 267 days in 2026Q2, alongside asset turnover rising from 0.11 to 0.24, indicates improving commercial utilization, though both remain low relative to asset-heavy pharmaceutical manufacturers.

The minimal spread between current and quick ratios confirms the business carries little inventory risk, meaning liquidity stress scenarios would hinge almost entirely on cash burn rather than asset realization, which appears comfortable given the reported cash position above $41M and zero total debt as of 2025Q4. Relative to peers such as Sonoma Pharmaceuticals at a 0.66 price-to-book, FENC's liquidity appears structurally superior, though the ratio has compressed from 8.02 in 2024Q2, suggesting working capital deployment is normalizing as operations scale.

The negative trailing P/E versus positive forward P/E suggests the market is pricing a rebound from historically loss-making quarters, but given the 2024Q1 milestone spike of 50.6% net margin, the earnings base is lumpy enough that the 37x forward multiple is unstable and hard to anchor to a growth rate. The 8.26x price-to-sales ratio versus peers like Lineage Cell Therapies, whose ROE sits at -73.1%, implies FENC carries a premium for its commercialized royalty stream, though whether that premium is warranted depends on milestone revenue recurrence, an issue investors should monitor.